The highest dose of an experimental pill developed by Eli Lilly dramatically lowered an inherited form of high cholesterol in a mid-stage trial, according to data presented at a medical meeting on ...

Hold on to your huaraches: as part of its 65th anniversary, Lilly Pulitzer is dipping a pastel-painted toe into the world of ...

Her earlier work with the paper’s investigations group, which examined how the Covid-19 pandemic ravaged nursing homes, was ...

Enjoy exclusive member discounts, giveaways and competitions with our subscriber rewards program. Sign upCatch cricket with a WACA Membership! See all International, Perth Scorchers and Domestic ...

Barclays analyst Carter Gould maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today and set a price target of $975.00. The company’s shares closed yesterday at $846.83.

(AP Photo/Peter Morgan) Updated [hour]:[minute] [AMPM] [timezone], [monthFull] [day], [year] NEW YORK (AP) — U.S. stock indexes edged lower Wednesday after drops for Eli Lilly and chip companies ...

Eli Lilly and Company reported third quarter results and missed expectations and had to lower its guidance, which was a huge disappointment for investors. But in the last few years, Eli Lilly was ...

Eli Lilly on Wednesday fell short of profit and revenue expectations for the third quarter, weighed down by disappointing sales of its blockbuster weight loss drug Zepbound and diabetes treatment ...

Copyright 2024 The Associated Press. All Rights Reserved. FILE - This April 26, 2017 file photo shows the Eli Lilly & Co. corporate headquarters in Indianapolis. (AP ...

Drug maker Eli Lilly’s share price plunged Wednesday morning after the company reported worse third-quarter results than expected, especially in its weight-loss drug division, registering a rare ...

Eli Lilly reported Q3 revenue and earnings that fell short of analysts' expectations. Mounjaro and Zepbound faced challenges as U.S. wholesalers reduced inventories of the drugs. The bull case for ...

Eli Lilly has dropped (PDF) the lead candidate from its $2.4 billion takeover of Dice Therapeutics, shifting the focus of its oral IL-17 psoriasis program to a follow-up molecule. Lilly kicked DC ...